Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-05-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
第四届监事会第七次会议决议公告
Governance Information Classification · 95% confidence The document is a formal announcement of a resolution passed by the Supervisory Board (监事会) of Yunnan Watson Biotechnology Co., Ltd. It details the meeting date, attendance, the agenda item (approval of amendments to the company's articles of association), and the voting results. It also mentions that the proposal will be submitted to the shareholders' meeting for approval. The document does not contain financial statements, audit results, or detailed financial data. It is a regulatory announcement about board-level decisions and governance matters, specifically about amendments to the company charter. This fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is not a full report, nor an announcement of a report publication, nor a shareholder voting result announcement. Therefore, the classification is CGR with high confidence.
2020-05-12 Chinese
关于2018年股票期权激励计划部分已授予股票期权注销完成的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the cancellation of part of the stock options granted under the 2018 stock option incentive plan. It details the board meeting resolutions, the number of stock options cancelled, and confirmation of completion of the cancellation process by the securities registration authority. The document is short (768 characters) and serves as an official announcement of a corporate action related to stock options, not a full report or financial statement. It does not contain financial results, management discussion, or detailed financial data. This fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2020-05-11 Chinese
关于深圳证券交易所关注函的回复
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or financial data. It is extremely short (324 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it does not fit any specific report category and should be classified as a Regulatory Filing (RNS) by fallback rule.
2020-05-11 Chinese
关于二价HPV疫苗Ⅲ期临床试验获得临床试验报告的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the receipt of Phase III clinical trial reports for their bivalent HPV vaccine. It discusses the clinical trial results, the vaccine's efficacy, and the next steps for regulatory approval. The document does not contain financial statements, detailed financial analysis, or management discussion of financial results. It is a regulatory announcement about clinical trial progress and future regulatory filings. The document length is short (1128 characters), and it serves as an official announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-30 Chinese
关于公司高管辞职的公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from a company about the resignation of a senior executive (engineering technology director). It includes details about the resignation, effective date, and impact on the company. There is no financial data, no mention of a report or meeting, and it focuses solely on management change. This fits the definition of 'Board/Management Information' (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2020-04-30 Chinese
关于股东减持股份计划实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholder's plan to reduce their shareholding in the company. It details the dates, quantities, and prices of shares sold, as well as compliance with relevant regulations. It does not contain financial statements, management discussion, or detailed financial results. The document is focused on reporting a transaction by a major shareholder and the completion of a share reduction plan. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.